Changes to the website
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

This is a list of chages to the website.

You can Subscribe to our RSS FEED: Subscribe to our RSS feed, which delivers brain tumor news and additions to the website via RSS.
(Click HERE for details on RSS.)

Displaying items 26 to 50 of about 4658

Previous 25           Next 25
Website Changes
07/13/2015 Ottawa Hospital launches world`s first clinical trial of double-virus cancer treatment
07/13/2015 FDA Grants Fast Track Designation to Tocagen’s Toca 511 & Toca FC for Treatment of Recurrent High Grade Glioma
07/06/2015 Epigenetic Driver of Glioblastoma Provides New Therapeutic Target
07/06/2015 An Evidence-Based Review of Alternating Electric Fields Therapy for Malignant Gliomas.
07/05/2015 Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
07/05/2015 Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy.
07/01/2015 Tocagen June 2015 Newsletter
06/27/2015 Problem with our websites and email
06/27/2015 IBTA Newsletter
06/23/2015 FEATURED ON THE CERN-FOUNDATION WEB SITE, A BOOK ABOUT BRAIN TUMORS RASIES FUNDS FOR RESEARCH. WRITTEN BY A BRAIN TUMOR SRVIVIOR, A POINGNANT STORY OF A FAMILY STRUGGLING WITH BRAIN CANCER.
06/20/2015 New City Of Hope Clinical Trial Harnesses The Power Of The Immune System To Fight Brain Cancers
06/18/2015 Human cytomegalovirus infection in tumor cells of the nervous system is not detectable with standardized pathologico-virological diagnostics
06/13/2015 Free summer camp in NJ - Camp Jinka
06/05/2015 The Musella Foundation announced that it has awarded Tocagen Inc. a grant to support preclinical testing the compatibility of Tocagen’s therapy with 5-ALA or tumor treating fields.
06/04/2015 Blaze Bioscience Announces Open Enrollment for Phase 1 Clinical Trial of Tumor Paint BLZ-100 in Children with Brain Cancer
06/03/2015 Development of resistance to antiglioma agents in rat C6 cells caused collateral sensitivity to doxorubicin.
06/03/2015 Randomized Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Overall Survival and Emergence of Long-term Survival Benefit; Primary Endpoint of PFS6 Met
05/31/2015 Novocure Announces First Analysis of Full 700 Patient Dataset from Successful Newly Diagnosed GBM Phase III Trial
05/31/2015 MUSELLA FOUNDATION AWARDS 6 BRAIN TUMOR RESEARCH GRANTS
05/28/2015 Novocure Announces Commercial Launch of Optune (the NovoTTF-100A System) in Japan
05/28/2015 MN Brain Tumor 5K Breaks Previous Record for Attendance, Fundraising
05/28/2015 Adding Bevacizumab (Avastin) Has No Impact on Quality of Life in Glioblastoma
05/28/2015 Novocure Hosts First Glioblastoma-focused Hackathon to Develop New Support Tools for the GBM Brain Cancer Community
05/26/2015 IBTA e-News
05/26/2015 Risk of surgical site infection in 401 consecutive patients with glioblastoma with and without carmustine wafer implantation



Home | Brain Tumor Guide | Search | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure NovoTTF-100A | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us | Doctors Address Book



Copyright (c) 1993 - 2015 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites